
|Articles|February 15, 2016
FDA Warning to Cannabidiol Suppliers
Author(s)Randi Hernandez
February 15, 2016.
Advertisement
FDA sent out eight warning letters on earlier this month to various makers of a dietary supplement called cannabidiol, which is derived from the Cannabis plant. Cannabidiol, also known as CBD oil, is described as a nonpsychoactive dietary supplement that is purported to have numerous benefits, including anti-inflammatory and antiemetic properties.
However, FDA said the CBD oil products are being marketed as medications and have not been adequately tested to prove they are safe and effective.
See more on this story at Pharmaceutical Technology
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Evolving Relationship Between FDA and Biotech
2
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
3
The Implications of GLP-1s Replacing Oncology as the Key Value Driver
4
Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi
5




